Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Benedictuson Dec 22, 2023 10:20pm
213 Views
Post# 35798829

RE:Only 11 patients were enrolled in 2023….

RE:Only 11 patients were enrolled in 2023….
Dumbeldorfwhite wrote: I went back to last years year end NR and there were 52 patients enrolled at that time. That is such a disappointing enrollment rate. What in the companies experience makes them think they will get 37 in a year?

The MD&A is the best resource to confirm this information. The Dec 2202 MD&A showed 57 enrolled and treated patients, so 6 patients have been enrolled and treated in 2023. The 37 patient goal by end of 2024 is an absolute mystery to me. Roger was less than forthright on that detail in his recent interview, so we are left to speculate. My guess is they expect a BTD approval to enable an expedited enrollment rate.
<< Previous
Bullboard Posts
Next >>